Article
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Blood - 31 May 2012
Man Cheuk Him, Fung Tsz Kan, Ho Christa, Han Heron H C, Chow Howard C H, Ma Alvin C H, Choi William W L, Lok Si, Cheung Alice M S, Eaves Connie, Kwong Yok Lam, Leung Anskar Y H
Abstract excerpt
Internal tandem duplication (ITD) of the fms-related tyrosine kinase-3 (FLT3) gene occurs in 30% of acute myeloid leukemias (AMLs) and confers a poor prognosis. Thirteen relapsed or chemo-refractory FLT3-ITD(+) AML patients were treated with sorafenib (200-400 mg twice daily). Twelve patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.